Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper

Blood (2021) 138 (Supplement 1): 135.

https://doi.org/10.1182/blood-2021-145124

Published: 2021

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

Journal Articles

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Joachim Yahalom, Bouthaina Shbib Dabaja, Umberto Ricardi, Andrea Ng, N. George Mikhaeel, Ivan R. Vogelius, Tim Illidge, Shunan Qi, Andrew Wirth, Lena Specht

Blood (2020) 135 (21): 1829–1832.

https://doi.org/10.1182/blood.2020006028

Published: 2020

Includes: Supplemental data

Journal Articles

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Mayur Uttarwar, Shih-Yuan Lee, Hong Ren, Dana A. Kennedy, Andrei R. Shustov

Blood (2018) 131 (19): 2120–2124.

https://doi.org/10.1182/blood-2017-12-821009

Published: 2018

Includes: Supplemental data

Journal Articles

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov

Blood (2017) 130 (25): 2709–2717.

https://doi.org/10.1182/blood-2017-05-780049

Published: 2017

Includes: Supplemental data

Journal Articles

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Blood (2016) 128 (22): 1780.

https://doi.org/10.1182/blood.V128.22.1780.1780

Published: 2016

Journal Articles

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H Advani, MD, Pauline Brice, MD, Nancy L Bartlett, MD, Joseph D Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A Fanale, MD, Joseph M. Connors, Keenan Fenton, Dirk Huebner, MD, Juan Pinelli, Andrei R. Shustov

Blood (2016) 128 (22): 4144.

https://doi.org/10.1182/blood.V128.22.4144.4144

Published: 2016

Journal Articles

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A Fanale, MD, Steven M Horwitz, MD, Andres Forero-Torres, MD, Nancy L Bartlett, MD, Ranjana H Advani, MD, Barbara Pro, MD, Robert W Chen, MD, Andrew J Davies, FRCP PhD, Tim Illidge, PhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R Shustov, MD

Blood (2016) 128 (22): 2993.

https://doi.org/10.1182/blood.V128.22.2993.2993

Published: 2016

Journal Articles

Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up

Steven M Horwitz, MD, Andrei R. Shustov, MD, Andres Forero-Torres, Nancy L Bartlett, MD, Ranjana Advani, Barbara Pro, Robert Chen, Andrew J Davies, MRCP, Tim Illidge, Dirk Huebner, Dana A. Kennedy, Michelle A. Fanale

Blood (2015) 126 (23): 1537.

https://doi.org/10.1182/blood.V126.23.1537.1537

Published: 2015

Journal Articles

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, Jeffrey Matous, MD, Radhakrishnan Ramchandern, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yinghui Wang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, BCOP, Andrei R. Shustov, MD

Blood (2014) 124 (21): 3095.

https://doi.org/10.1182/blood.V124.21.3095.3095

Published: 2014

Journal Articles

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert Chen, MD, Andrew Davies, BM PhD, Tim Illidge, PhD, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 4386.

https://doi.org/10.1182/blood.V122.21.4386.4386

Published: 2013

Journal Articles

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 1809.

https://doi.org/10.1182/blood.V122.21.1809.1809

Published: 2013

Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Blood (2012) 120 (21): 3701.

https://doi.org/10.1182/blood.V120.21.3701.3701

Published: 2012

Journal Articles

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey V. Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2012) 120 (21): 2745.

https://doi.org/10.1182/blood.V120.21.2745.2745

Published: 2012

Journal Articles

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

Michelle A. Fanale, MD, Andrei R. Shustov, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, MD, Tim Illidge, PhD, Dana A. Kennedy, PharmD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 60.

https://doi.org/10.1182/blood.V120.21.60.60

Published: 2012

Journal Articles

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

Jean-Francois Larouche, MD, Marc Bergeron, MD, Grace Hampson, Tim Illidge, Robert Delage, MD, MSc, FRCP

Blood (2011) 118 (21): 1644.

https://doi.org/10.1182/blood.V118.21.1644.1644

Published: 2011

Journal Articles

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Tim Illidge, Reda Bouabdallah, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Craig H. Moskowitz, MD, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, MD, Andrei R. Shustov, MD, Herve Tilly, MD, Tanya Trippett, MD, Laurie E. Grove, PA-C, Ranjana H. Advani, MD

Blood (2011) 118 (21): 3091.

https://doi.org/10.1182/blood.V118.21.3091.3091

Published: 2011

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Ranjana H. Advani, MD, Andrei R. Shustov, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2011) 118 (21): 443.

https://doi.org/10.1182/blood.V118.21.443.443

Published: 2011

Journal Articles

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Andrei R. Shustov, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Eric L. Sievers, MD, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2010) 116 (21): 961.

https://doi.org/10.1182/blood.V116.21.961.961

Published: 2010

Journal Articles

Anti-HLA-DR Monoclonal Antibody Evokes a Novel Non-Apoptotic Cell Death Pathway In Acute Lymphoblastic Leukemia

Khimara Naidoo, Waleed Alduaij, Jamie Honeychurch, Eleanor Cheadle, Seema Alexander, Richard Byers, Vaskar Saha, Tim Illidge

Blood (2010) 116 (21): 3245.

https://doi.org/10.1182/blood.V116.21.3245.3245

Published: 2010

NARROW

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Anti-HLA-DR Monoclonal Antibody Evokes a Novel Non-Apoptotic Cell Death Pathway In Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only